BRIDGEWATER, N.J. and BENGALURU, India, July 3, 2023 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, today announced that HULIO® (adalimumab-fkjp) injection, a biosimilar to ...

Biocon Biologics, a subsidiary of Biocon has announced that Hulio (adalimumab-fkjp) injection, a biosimilar to Humira (adalimumab), is now available to patients in the United States after five years ...

HULIO is similar to another injection called Humira manufactured by AbbVie Inc. Biocon Biologics’ HULIO is available at a 5 percent discount as compared to the already existing inflammatory injection ...

A biosimilar drugs have a similar composition to another biological drug (called the reference drug) that has been approved by the U.S. FDA. Biocon Biologics Ltd , a subsidiary of Bangalore-based ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the sixth biosimilar to adalimumab, adalimumab-fkjp, for all eligible indications of the ...

Please provide your email address to receive an email when new articles are posted on . The researchers added that, “subsequently, [biosimilar adalimumab] effectiveness and safety were proved in two ...

its acquisition of Viatris' global biosimilars business, has secured multiple biosimilar approvals in the U.S., Europe, and over 100 countries across the globe. With the acquisition of Viatris' ...

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, today announced that HULIO (adalimumab-fkjp) injection, a biosimilar to Humira (adalimumab), is now available to patients in the United States a ...